Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
Authors:
Open Access
- 14 May 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (26) , 23015-23025
Abstract
Up to 15% of patients with cervical cancer and pN0-status develop recurrent-disease. This may be due to occult metastatic spread of tumor cells. We evaluated the use of human-papillomavirus-(HPV)-mRNA as a molecular marker for disseminated tumor cells to predict the risk of recurrence. For this prospective, multi-center prognostic study, 189 patients free of lymphnode metastases by conventional histopathology could be analyzed. All patients underwent complete lymphadenectomy. Of each sentinel node (SLN) a biopsy was taken for the detection of HPV-E6-E7-mRNA. Median follow-up time after surgery was 8.1 years. HPV-mRNA could be detected in SLN of 52 patients (27.5%). Recurrence was observed in 22 patients. Recurrence-free-survival was significantly longer for patients with HPV-negative SLN (log rank p = 0.002). By Cox regression analysis the hazard ratio (95%CI) for disease-recurrence was 3.8 (1.5 – 9.3, p = 0.004) for HPV-mRNA-positive compared to HPV-mRNA-negative patients. After adjustment for tumor size as the most influential covariate the HR was still 2.8 (1.1 – 7.0, p = 0.030). In patients with cervical cancer and tumor-free lymph nodes by conventional histopathology HPV-mRNA-positive SLN were of prognostic value independent of tumor size. Particularly, patients with tumors larger than 20mm diameter could possibly benefit from further risk stratification using HPV-mRNA as a molecular marker.Keywords
This publication has 25 references indexed in Scilit:
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- Clinical significance of sentinel lymph node isolated tumour cells in breast cancerBreast Cancer Research and Treatment, 2011
- The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cmGynecologic Oncology, 2010
- Multicenter Validation Study of the Sentinel Lymph Node Concept in Cervical Cancer: AGO Study GroupJournal of Clinical Oncology, 2008
- Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcriptsOncogene, 2007
- HPV16‐E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse‐transcription PCRInternational Journal of Cancer, 2007
- Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage MelanomaAnnals of Surgery, 2003
- Molecular quantification and mapping of lymph-node micrometastases in cervical cancerThe Lancet, 2001
- An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992